FreeTheAI

Sanara MedTech Receives FTC Request for More Info on MiMedx Merger

NeutralMedium impact
SMTI$34.10 −2.82%

Sanara MedTech, Inc. (SMTI) announced that the U.S. Federal Trade Commission requested additional documentation regarding its proposed combination with MiMedx. The regulatory inquiry was formally issued on October 15, 2026, as part of the antitrust review under the Hart-Scott-Rodino Act.

The regulatory inquiry automatically extends the required waiting period under antitrust rules. Completion of the deal will now be paused until 30 days after both medical technology companies substantially comply with the request for information, unless federal officials terminate the review early or agree to an extension.

Sanara MedTech stated that it is fully cooperating with regulators and intends to continue working constructively throughout the antitrust assessment. Finalizing the transaction remains subject to completing the statutory waiting timeline alongside fulfilling or waiving other customary closing terms.

Key points

  • The U.S. Federal Trade Commission requested additional information regarding Sanara MedTech's merger with MiMedx on October 15, 2026.
  • The review period under the Hart-Scott-Rodino Act is extended until 30 days after substantial compliance with the request.
  • Sanara MedTech is cooperating with antitrust regulators as the review process continues.
  • Closing the deal depends on resolving the regulatory waiting period and satisfying remaining merger terms.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why was Sanara MedTech's merger with MiMedx delayed?

The Federal Trade Commission issued a Second Request for additional information and documents, which extends the mandatory regulatory review period under antitrust regulations.

How long is the FTC review waiting period extended for Sanara MedTech?

The waiting period under the Hart-Scott-Rodino Act is extended until 30 days after the companies achieve substantial compliance with the FTC's request.

Is Sanara MedTech still moving forward with the MiMedx acquisition?

Yes, Sanara MedTech is actively cooperating with regulators and working to fulfill all conditions needed to complete the transaction.